VISANO: Revolutionizing Cancer Diagnosis and Treatment with Nanobubbles
In the ever-evolving fight against cancer, innovation is crucial. Traditional diagnostic tools have their limitations—particularly in oncology where early, precise detection is vital. That’s where VISANO steps in, offering a groundbreaking approach through tiny contrast agents that are reshaping the future of cancer diagnosis and treatment.
Why Microbubbles Are Falling Short
Microbubble-based contrast agents have been used in ultrasound imaging for decades, but they present several critical drawbacks, especially in oncology:
- They cannot leave the vasculature, meaning they don’t have direct access to target cancer cells.
- Targeting extraluminal biomarkers is impossible due to their size and structural limitations.
- Their circulation time is very short, lasting only a few minutes, limiting their usefulness in clinical applications.
- They require low-frequency transducers, making them unsuitable for detailed imaging of small or complex body parts.
- And perhaps most significantly—there’s been little innovation in this field for over 20 years.
Clearly, a new solution is needed. Enter Nanobubbles.
The Nanobubble Advantage
VISANO’s cutting-edge nanobubble technology offers a host of advantages over traditional microbubbles:
- Extravascular Applications: Unlike microbubbles, nanobubbles (~200–600 nm in diameter) can leave the bloodstream and interact directly with cancer cells.
- Targeted Imaging: They can be designed to bind to specific cancer cell biomarkers, enhancing the precision of diagnosis and treatment monitoring.
- High-Frequency Compatibility: Nanobubbles work effectively with high-frequency ultrasound (US), enabling clear imaging of small, critical areas.
- Expanded CEUS Potential: With VISANO’s technology, contrast-enhanced ultrasound (CEUS) becomes more viable for imaging of “small parts” like the thyroid, breast, and testes—areas previously challenging with traditional methods.
A Paradigm Shift in Cancer Care
VISANO is not just another contrast agent; it’s a transformative leap in medical imaging. By addressing the long-standing limitations of microbubbles and unlocking new clinical possibilities, VISANO’s nanobubbles could significantly improve outcomes for cancer patients worldwide.